The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Regulatory News (COG)

Share Price Information for Cambridge Cog (COG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 48.50
Bid: 48.00
Ask: 49.00
Change: 0.00 (0.00%)
Spread: 1.00 (2.083%)
Open: 48.80
High: 48.80
Low: 48.50
Prev. Close: 48.50
COG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

18 Jan 2023 13:14

RNS Number : 1580N
Cambridge Cognition Holdings PLC
18 January 2023
 

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Cambridge Cognition Holdings plc

1a. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii: Change in Total Voting rights of issuer

x

1. Details of person subject to the notification obligationiv

Name

NIGEL WRAY

City and country of registered office (if applicable)

LONDON, U.K.

2. Full name of shareholder(s) (if different from 3.)v

Name

UBS PRIVATE BANKING NOMINEES LTDJARVIS INVESTMENT MANAGEMENTNOMINEES LIMITED

City and country of registered office (if applicable)

LONDON, U.K.

3. Date on which the threshold was crossed or reachedvi:

16 January 2023

4. Date on which issuer notified (DD/MM/YYYY):

18/01/2023

5. Total positions of person(s) subject to the notification obligation

% of voting rightsattached to shares(total of 8. A)

% of voting rightsthrough financialinstruments(total of 8.B 1 + 8.B 2)

Total of both in %(8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

14.5210%

14.5210%

5,026,547

 

Position of previous

notification (if applicable)

16.1262%

16.1262%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type of

shares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive2004/109/EC)(DTR5.2.1)

Direct

(Art 9 of Directive2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive2004/109/EC)(DTR5.2.1)

ORDINARY SHARES

5,026,547

14.5210%

GB00B8DV9647

SUBTOTAL 8. A

5,026,547

14.5210%

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expiration datex

Exercise/

Conversion Periodxi

Number of voting rights that may be acquired if the instrument is exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

B 1: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/ Conversion Period xi

Physical orcash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL8.B.2

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings

through which the voting rights and/or the

held starting with the ultimate controlling natural person or legal entity xiv

necessary)

X

financial instruments are effectively (please add additional rows as

Namexv

% of voting rights if itequals or is higherthan the notifiablethreshold

% of voting rightsthrough financialinstruments if it equalsor is higher than thenotifiable threshold

Total of both if itequals or is higherthan the notifiablethreshold

Nigel Wray has a beneficial interest in shares held by UBS PRIVATE BANKING NOMINEES LTD

JARVIS INVESTMENT MANAGEMENT

NOMINEES LIMITED

14.5210%

14.5210%

 

1. In case of proxy voting, please identify:

Name of the proxy holder

N/A

The number and % of voting rights held

N/A

The date until which the voting rights will be held

N/A

 

1. Additional informationxvi

Of the shares in (8) above, 314,000 shares are held as a trustee of The Priory Foundation, a charitable trust in which I have no beneficial interest.

Place of completion Date of completion

London

18 January 2023

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLBPMJTMTBBBTJ
Date   Source Headline
16th Mar 20167:00 amRNSTrading Update
1st Mar 20167:00 amRNSWearables partnership
15th Feb 20167:00 amRNSDirectorate Change
8th Dec 20157:00 amRNSNew medical device
20th Nov 20157:00 amRNSYear End Trading Update
8th Oct 20157:00 amRNSTwo software licence agreements
21st Sep 20157:00 amRNSFormation of Cantab Corporate Health Limited
10th Sep 20157:00 amRNSHalf Yearly Report
9th Sep 20157:00 amRNSNew patent application
20th Aug 20157:00 amRNSNotice of Results
22nd Jul 20152:30 pmRNSNew research delivered at AAIC
9th Jul 201512:08 pmRNSDirector dealing and Grant of Options
8th Jul 20155:15 pmRNSRe: Directorate Change
1st Jul 201512:00 pmRNSAppointment of Chief Operating Officer
8th Jun 20158:53 amRNSDirector dealing
2nd Jun 201510:30 amRNSAppointment of Non-Executive Director
27th May 201510:33 amRNSResult of AGM
27th May 20157:00 amRNSAGM Statement
21st May 20153:17 pmRNSIssue of Equity
20th May 20157:00 amRNSNew cognitive assessment product
12th May 20157:01 amRNSInvestor teach-in
6th May 20159:35 amRNSHolding(s) in Company
6th May 20157:02 amRNSNew Applications in Healthcare
1st May 201512:02 pmRNSPosting of Annual Report & Notice of AGM
14th Apr 20157:00 amRNSSales of Cantab Connect iPad product exceed £1m
12th Mar 20157:00 amRNSFinal Results
4th Mar 20157:00 amRNSUS office opened
3rd Mar 20157:00 amRNSNotice of Results
21st Jan 20157:00 amRNSLaunch of new iPad research product
16th Dec 20143:12 pmRNSHolding(s) in Company
15th Dec 20149:21 amRNSDirector/PDMR Shareholding
21st Nov 20145:13 pmRNSDirector Declaration
30th Oct 20147:00 amRNSSupporting the Dementias Research Platform UK
23rd Oct 20147:00 amRNSLaunch of CTIS-Profile 2+ on Cantab Connect
1st Oct 20147:00 amRNSDirector/PDMR Shareholding
29th Sep 201412:40 pmRNSReplacement - Director/PDMR Shareholding
29th Sep 201410:06 amRNSDirector/PDMR Shareholding
24th Sep 201410:22 amRNSHolding(s) in Company
24th Sep 20147:00 amRNSDirector/PDMR Shareholding
23rd Sep 20141:29 pmRNSHolding(s) in Company
18th Sep 201411:57 amRNSIssue of Equity
11th Sep 20147:00 amRNSHalf Yearly Report
13th Aug 20147:00 amRNSExpands collaboration with Altreos
15th Jul 20147:00 amRNSNew research delivered at AAIC
3rd Jul 20144:58 pmRNSHolding(s) in Company
2nd Jul 20147:00 amRNSHalf Year Pre-Close Update
26th Jun 20147:00 amRNSHuman Abuse and Liability trial contracts won
5th Jun 20147:00 amRNS£1.6m phase III cognitive safety trial
3rd Jun 20147:00 amRNSLaunch of first two products on new platform
28th May 20147:00 amRNSCantab Mobile rolled out in NE Lincolnshire CCG

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.